首页> 美国卫生研究院文献>Allergy Rhinology >The rate of epinephrine administration associated with allergy skin testing in a suburban allergy practice from 1997 to 2010
【2h】

The rate of epinephrine administration associated with allergy skin testing in a suburban allergy practice from 1997 to 2010

机译:从1997年到2010年在郊区的过敏症实践中与过敏性皮肤测试有关的肾上腺素给药比例

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Allergy skin testing is considered a safe method for testing for IgE-mediated allergic responses although anaphylactic events can occur. Reported rates of anaphylaxis per patient are not consistent and range from 0.008 to 4%. The aim of this study was to determine the rate of epinephrine use associated with allergy skin-prick testing (SPT) and intradermal testing (IDT) in a suburban practice over 13 years. This retrospective chart review used billing and procedure coding records during the time period from January 1997 to June 2010 to identify encounters where epinephrine was administered after SPT or IDT. Patient encounters with procedure codes for skin testing plus either parenteral epinephrine, corticosteroid, antihistamine, or i.v. fluid administration were identified. These patient charts were reviewed to determine if epinephrine was administered, whether systemic reactions developed, and rates of epinephrine administration were calculated. There were 28,907 patient encounters for SPT and 18,212 for IDT. Epinephrine was administered in six patient encounters (0.02%) where SPT was performed; no IDT encounters led to epinephrine administration. There were no fatalities. Allergy skin testing to a variety of allergens, when administered by well-trained personnel, is a safe procedure. This study, involving the largest population to date, showed a rate of systemic reactions requiring epinephrine of 20 per 100,000 SPT visits. No epinephrine was given after IDT.
机译:尽管可能发生过敏事件,但过敏性皮肤测试被认为是测试IgE介导的过敏反应的安全方法。报告的每位患者的过敏反应率不一致,范围为0.008%至4%。这项研究的目的是确定在郊区实践中使用肾上腺素与过敏性皮肤点刺试验(SPT)和皮内试验(IDT)相关的比率超过13年。该回顾性图表审查使用了1997年1月至2010年6月期间的帐单和程序编码记录,以识别在SPT或IDT后使用肾上腺素的情况。病人遇到皮肤测试的程序代码以及肠胃外肾上腺素,皮质类固醇,抗组胺药或静脉注射。确定了输液。回顾了这些患者图表,以确定是否使用了肾上腺素,是否发生全身反应以及计算了肾上腺素的施用率。 SPT有28907例患者遭遇IDT,有18212例IDT。在进行SPT的六例患者中(0.02%)给予肾上腺素;没有遇到IDT导致肾上腺素的管理。没有死亡。由训练有素的人员对各种过敏原进行过敏性皮肤测试是一种安全的程序。这项研究涉及迄今为止最大的人群,显示需要每100,000例SPT进行20次肾上腺素的全身反应。 IDT后未给予肾上腺素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号